Objetivo The power of 3D X-ray imaging in healthcare in the form of Computed Tomography (CT) is widely accepted, but despite the widespread availability of CT and Magnetic Resonance Imaging (MRI) it is still the basic 2D planar X-ray that constitutes the majority (circa 60%) of medical imaging studies worldwide. Planar X-ray continues to be the “workhorse of radiology” because of its availability, low cost and small system footprint (compared to MRI and CT); its speed of image acquisition and review (compared to all other modalities); its ability to visualize tissues like bone (unlike MRI and Ultrasound); its low radiation dose (unlike CT); and its consistency and objectivity of image acquisition (unlike Ultrasound).Tomosynthesis, a method for performing high-resolution limited-angle tomography at low dose levels, has already transformed breast cancer screening and has demonstrated an ability to near-equal CT in identifying lung nodules symptomatic of lung cancer.Our innovation is a Flat Panel X-ray Source (FPS) that allows tomosynthesis without any moving parts. This will reduce costs and enhance acquisition speed and allows the source to be closer to the subject, reducing power needs and further reducing cost.Unlike current tomosynthesis devices that move the source in 1 dimension, a system using an FPS could vary emission in 2 dimensions which could enhance depth resolution and the ability to localise objects. This would enhance the ability to quantify features, including biomarkers of disease progression.Adaptix will transform planar X-ray by giving it true 3D capability, making it safer by reducing dose (versus CT, and potentially versus planar X-ray), making the systems 50% cheaper than existing market offerings and reducing weight and size by 90%. By doing this we will be improving access to the world’s most important medical diagnostic device and radically changing a $5bn global market. Ámbito científico medical and health sciencesclinical medicineoncologylung cancerengineering and technologymedical engineeringdiagnostic imagingcomputed tomographymedical and health sciencesclinical medicineradiologymedical and health sciencesclinical medicineoncologybreast cancernatural sciencesphysical sciencesacousticsultrasound Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2015 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador ADAPTIX LTD Aportación neta de la UEn € 50 000,00 Dirección BEGBROKE SCIENCE PARK - WOODSTOCK ROAD OX5 1PF OXFORD Reino Unido Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00